These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
122 related articles for article (PubMed ID: 1672668)
1. Selection of monoclonal antibodies which induce internalization and phosphorylation of p185HER2 and growth inhibition of cells with HER2/NEU gene amplification. Tagliabue E; Centis F; Campiglio M; Mastroianni A; Martignone S; Pellegrini R; Casalini P; Lanzi C; Ménard S; Colnaghi MI Int J Cancer; 1991 Apr; 47(6):933-7. PubMed ID: 1672668 [TBL] [Abstract][Full Text] [Related]
2. Antibody-induced activation of p185HER2 in the human lung adenocarcinoma cell line Calu-3 requires bivalency. Srinivas U; Tagliabue E; Campiglio M; Ménard S; Colnaghi MI Cancer Immunol Immunother; 1993 Jun; 36(6):397-402. PubMed ID: 8098992 [TBL] [Abstract][Full Text] [Related]
4. Regulation of phosphorylation of the c-erbB-2/HER2 gene product by a monoclonal antibody and serum growth factor(s) in human mammary carcinoma cells. Kumar R; Shepard HM; Mendelsohn J Mol Cell Biol; 1991 Feb; 11(2):979-86. PubMed ID: 1671297 [TBL] [Abstract][Full Text] [Related]
5. Monoclonal antibody therapy of human cancer: taking the HER2 protooncogene to the clinic. Shepard HM; Lewis GD; Sarup JC; Fendly BM; Maneval D; Mordenti J; Figari I; Kotts CE; Palladino MA; Ullrich A J Clin Immunol; 1991 May; 11(3):117-27. PubMed ID: 1679763 [TBL] [Abstract][Full Text] [Related]
6. Antibody-induced growth inhibition is mediated through immunochemically and functionally distinct epitopes on the extracellular domain of the c-erbB-2 (HER-2/neu) gene product p185. Xu F; Lupu R; Rodriguez GC; Whitaker RS; Boente MP; Berchuck A; Yu Y; DeSombre KA; Boyer CM; Bast RC Int J Cancer; 1993 Feb; 53(3):401-8. PubMed ID: 7679090 [TBL] [Abstract][Full Text] [Related]
7. Inhibition of human lung cancer cell line growth by an anti-p185HER2 antibody. Kern JA; Torney L; Weiner D; Gazdar A; Shepard HM; Fendly B Am J Respir Cell Mol Biol; 1993 Oct; 9(4):448-54. PubMed ID: 8104437 [TBL] [Abstract][Full Text] [Related]
8. p185, a product of the neu proto-oncogene, is a receptorlike protein associated with tyrosine kinase activity. Stern DF; Heffernan PA; Weinberg RA Mol Cell Biol; 1986 May; 6(5):1729-40. PubMed ID: 2878363 [TBL] [Abstract][Full Text] [Related]
9. Mutation of the human neu protein facilitates down-modulation by monoclonal antibodies. van Leeuwen F; van de Vijver MJ; Lomans J; van Deemter L; Jenster G; Akiyama T; Yamamoto T; Nusse R Oncogene; 1990 Apr; 5(4):497-503. PubMed ID: 1970152 [TBL] [Abstract][Full Text] [Related]
10. Differential responses of human tumor cell lines to anti-p185HER2 monoclonal antibodies. Lewis GD; Figari I; Fendly B; Wong WL; Carter P; Gorman C; Shepard HM Cancer Immunol Immunother; 1993 Sep; 37(4):255-63. PubMed ID: 8102322 [TBL] [Abstract][Full Text] [Related]
11. Phosphorylation process induced by epidermal growth factor alters the oncogenic and cellular neu (NGL) gene products. Kokai Y; Dobashi K; Weiner DB; Myers JN; Nowell PC; Greene MI Proc Natl Acad Sci U S A; 1988 Aug; 85(15):5389-93. PubMed ID: 2899889 [TBL] [Abstract][Full Text] [Related]
12. Characterization of murine monoclonal antibodies reactive to either the human epidermal growth factor receptor or HER2/neu gene product. Fendly BM; Winget M; Hudziak RM; Lipari MT; Napier MA; Ullrich A Cancer Res; 1990 Mar; 50(5):1550-8. PubMed ID: 1689212 [TBL] [Abstract][Full Text] [Related]
13. Monoclonal antibodies specific for the neu oncogene product directly mediate anti-tumor effects in vivo. Drebin JA; Link VC; Greene MI Oncogene; 1988 Apr; 2(4):387-94. PubMed ID: 2896329 [TBL] [Abstract][Full Text] [Related]
14. The extracellular domain of the c-erbB-2 oncoprotein is released from tumor cells by proteolytic cleavage. Pupa SM; Ménard S; Morelli D; Pozzi B; De Palo G; Colnaghi MI Oncogene; 1993 Nov; 8(11):2917-23. PubMed ID: 8105438 [TBL] [Abstract][Full Text] [Related]
15. Antigenic and immunogenic mimicry of the HER2/neu oncoprotein by phage-displayed peptides. Orlandi R; Ménard S; Colnaghi MI; Boyer CM; Felici F Eur J Immunol; 1994 Nov; 24(11):2868-73. PubMed ID: 7525309 [TBL] [Abstract][Full Text] [Related]
16. Humanization of an anti-p185HER2 antibody for human cancer therapy. Carter P; Presta L; Gorman CM; Ridgway JB; Henner D; Wong WL; Rowland AM; Kotts C; Carver ME; Shepard HM Proc Natl Acad Sci U S A; 1992 May; 89(10):4285-9. PubMed ID: 1350088 [TBL] [Abstract][Full Text] [Related]
17. Radiolabeled antibody targeting of the HER-2/neu oncoprotein. De Santes K; Slamon D; Anderson SK; Shepard M; Fendly B; Maneval D; Press O Cancer Res; 1992 Apr; 52(7):1916-23. PubMed ID: 1348016 [TBL] [Abstract][Full Text] [Related]
18. Anti-p185HER2 monoclonal antibodies: biological properties and potential for immunotherapy. Park JW; Stagg R; Lewis GD; Carter P; Maneval D; Slamon DJ; Jaffe H; Shepard HM Cancer Treat Res; 1992; 61():193-211. PubMed ID: 1360232 [No Abstract] [Full Text] [Related]
19. The epidermal growth factor receptor and the product of the neu protooncogene are members of a receptor tyrosine phosphorylation cascade. Connelly PA; Stern DF Proc Natl Acad Sci U S A; 1990 Aug; 87(16):6054-7. PubMed ID: 1974718 [TBL] [Abstract][Full Text] [Related]
20. Colocalization of the p185HER2 oncoprotein and integrin alpha 6 beta 4 in Calu-3 lung carcinoma cells. Campiglio M; Tagliabue E; Srinivas U; Pellegrini R; Martignone S; Ménard S; Colnaghi MI; Lombardi L; Marchisio PC J Cell Biochem; 1994 Aug; 55(4):409-18. PubMed ID: 7962174 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]